Description
The MH3-2 monoclonal antibody specifically recognizes the human variable beta 5.2 (TCR Vβ5.2) and variable beta 5.3 (TCR Vβ5.3) domains of the beta subunit for the αβ T cell receptor (TCR Vβ5.2/5.3). The TCR Vβ5.2 and TCR Vβ5.3 domains are encoded by the TRBV5-6 (T cell receptor beta variable 5-6; also known as TCRBV5S2) and TRBV5-5 (T cell receptor beta variable 5-5; TCRBV5S3) gene segments of the multimembered Vβ5 subfamily within the TRB (T cell receptor beta locus), respectively. Functional T-cell receptor beta chains (TCR-β) are generated by genomic rearrangement of TCR variable (Vβ), diversity (Dβ), joining (Jβ) and constant (Cβ) region gene segments by precursor T cells. Distinct αβ TCR containing either TCR Vβ5.2 or TCR Vβ5.3 are clonally expressed on subsets of thymocytes or peripheral CD4+ or CD8+ T cells. These TCR β beta chains can heterodimerize with TCR α chains to form αβ TCR that function as signaling T cell receptors for antigen. Human αβ TCR recognize peptides presented by HLA (MHC) molecules and in conjunction with the associated CD3 complex, can transduce intracellular signals that initiate precursor or mature T cell responses. The MH3-2 antibody may be useful for analyzing the frequencies or numbers of TCR Vβ5.2/5.3-positive thymocytes or mature T cells as well as the levels of TCR Vβ5.2/5.3 expressed by these cells. The MH3-2 antibody can be used in research applications such as flow cytometry to help characterize the TCR Vβ repertoires of precursor or mature T cell populations.
Bead-based compensation or unmixing controls, such as BD® CompBeads or BD™ SpectraComp™, can be used as surrogates to assess fluorescence spillover when bound to fluorochrome-conjugated antibodies. Although these beads have spectral properties similar to cells, variations in spectral emission may occur, resulting in differing spillover values compared to biological controls. Therefore, it is considered best practice to compare the spillover obtained from cells and bead-based controls when using BD® CompBeads or BD™ SpectraComp™ for the first time, to ensure they are appropriate for the intended application.
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
2. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
3. For U.S. patents that may apply, see bd.com/patents.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
6. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
7. When using high concentrations of antibody, background binding of this dye to erythroid fragments produced by ammonium chloride-based lysis, such as with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899), has been observed when the antibody conjugate was present during the lysis procedure. This may cause nonspecific staining of target cells, such as leukocytes, which have bound the resulting erythroid fragments. This background can be mitigated by any of the following: titrating the antibody conjugate to a lower concentration, fixing samples with formaldehyde, or removing erythrocytes before staining (eg, gradient centrifugation or pre-lysis with wash). This background has not been observed when cells were lysed with BD FACS™ Lysing Solution (Cat. No. 349202) after staining.
8. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
9. An isotype control should be used at the same concentration as the antibody of interest.
10. Please observe the following precautions: We recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to protect exposure of conjugated reagents, including cells stained with those reagents, to any room illumination. Absorption of visible light can significantly affect the emission spectra and quantum yield of tandem fluorochrome conjugates.
11. Alexa Fluor™ is a trademark of Life Technologies Corporation.
12. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
